1. Home
  2. VFC vs ERAS Comparison

VFC vs ERAS Comparison

Compare VFC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo V.F. Corporation

VFC

V.F. Corporation

HOLD

Current Price

$16.07

Market Cap

6.6B

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$11.10

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VFC
ERAS
Founded
1899
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
5.5B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
VFC
ERAS
Price
$16.07
$11.10
Analyst Decision
Hold
Strong Buy
Analyst Count
18
12
Target Price
$18.24
$14.25
AVG Volume (30 Days)
6.7M
8.3M
Earning Date
05-20-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
80.72
36.23
EPS
0.95
N/A
Revenue
$10,488,556,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.06
N/A
P/E Ratio
$17.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.11
$1.06
52 Week High
$22.27
$24.28

Technical Indicators

Market Signals
Indicator
VFC
ERAS
Relative Strength Index (RSI) 31.83 41.69
Support Level $15.84 $1.76
Resistance Level $16.94 $16.14
Average True Range (ATR) 0.66 0.73
MACD -0.31 0.06
Stochastic Oscillator 6.73 76.58

Price Performance

Historical Comparison
VFC
ERAS

About VFC V.F. Corporation

VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: